Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anrotinib plus chemoradiotherapy for locally advanced esophageal squamous cell carcinoma
ChiCTR1900021280Phase 4Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR1900021280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021280.